Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases-Reference-Cited by-同舟云学术

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

Published:2019-06 Issue: Volume:71 Page:404-410
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Dumas Todd,Berry N. Seth,Wolfsegger Martin,Jolles Stephen^ORCID,McCoy Barbara,Yel Leman

Funder

Baxalta US Inc.

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference27 articles.

1. Update on the use of immunoglobulin in human disease: a review of evidence;Perez;J. Allergy Clin. Immunol.,2017

2. A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with primary immunodeficiency diseases: a systematic review and meta-analysis;Shabaninejad;Expert. Rev. Clin. Immunol.,2016

3. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose;Berger;Curr. Opin. Allergy Clin. Immunol.,2011

4. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again;Wasserman;J. Clin. Immunol.,2012

5. Hizentra® (Immune Globulin Subcutaneous [Human], 20% Liquid), Full Prescribing Information,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy;Annals of Clinical and Translational Neurology;2024-07-08

2. Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study;Immunotherapy Advances;2024-01-01

3. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies;International Immunopharmacology;2022-12

4. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases;International Immunopharmacology;2022-03

5. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases;International Immunopharmacology;2021-11